U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT06938282) titled 'An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer' on April 14.
Brief Summary: To evaluate the safety and efficacy of HRS-4642 in combination with immunotherapy and chemotherapy in borderline resectable, locally advanced/metastatic pancreatic cancer
Study Start Date: May 01
Study Type: INTERVENTIONAL
Condition:
Pancreatic Cancer
Intervention:
DRUG: HRS-4642
HRS-4642 in Combination with Immunotherapy and Chemotherapy
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shanghai Zhongshan Hospital
Published by HT Digital Content Services with permission from Health...